CJC-1295 (DAC-GHRH Analogue)
Overview
CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH 1–29) engineered for a very long duration of action. It carries four stabilising amino-acid substitutions and, in its DAC form, a group that binds covalently to circulating albumin — extending its half-life to several days and giving sustained GHRH-receptor activation. A “no-DAC” version (often called Modified GRF 1-29) is shorter-acting. It is a research compound.
Chemical Profile
| Property | Value |
|---|---|
| CAS number | 863288-34-8 (with DAC) |
| Class | GHRH(1–29) analogue with Drug-Affinity-Complex (DAC) technology |
| Backbone | Modified GHRH(1–29): D-Ala², Gln⁸, Ala¹⁵, Leu²⁷ substitutions + C-terminal Lys–DAC |
| Molecular weight (with DAC) | ≈ 3647 g/mol |
| Molecular weight (no-DAC / Mod GRF 1-29) | ≈ 3368 g/mol |
| Purity (HPLC) | ≥ 98% |
| Appearance | White to off-white lyophilized powder |
- Class
- GHRH analogue (DAC technology)
- Originator
- ConjuChem Biotechnologies
- Research status
- Phase 1/2 clinical research
- Study route
- Subcutaneous
- Half-life
- ≈ 6–8 days (albumin-bound, DAC form)
- Key feature
- Sustained GH / IGF-1 elevation for days
Mechanism of Action
CJC-1295 activates the GHRH receptor on pituitary somatotrophs, driving GH synthesis and release in a GHRH-like way (via Gαs and cAMP). Two engineering ideas extend its life: four amino-acid substitutions make it resistant to the DPP-4 enzyme, and — in the DAC form — a maleimide group binds albumin so the molecule circulates for days rather than minutes.
| Component | Detail |
|---|---|
| Primary target | GHRH receptor (GHRH-R) on somatotrophs |
| G-protein coupling | Gαs → adenylyl cyclase → cAMP → PKA |
| DPP-4 resistance | Four stabilising substitutions in the GHRH(1–29) core |
| Albumin binding (DAC) | Covalent binding extends circulating half-life to days |
| GH / IGF-1 | Sustained elevation with the natural pulsatile pattern preserved |
Pharmacology
| Parameter | Value |
|---|---|
| Half-life (t½) | ≈ 6–8 days (DAC form); short (no-DAC form) |
| Bioavailability (SC) | ≈ 70–80% |
| Time to peak (Tmax) | ≈ 12–24 h (DAC form) |
| Metabolism | Proteolytic degradation |
| Route of administration | Subcutaneous |
| Elimination | Renal (peptide fragments) |
Research Evidence
Representative studies and their focus are named below; specific numerical outcomes are not restated here as claims.
| Study type | Research focus | Reference |
|---|---|---|
| Healthy-volunteer study | Sustained GH / IGF-1 over multiple days | Teichman SL, et al. (2006) |
| GHRH-analogue pharmacology | DAC albumin-binding half-life extension | ConjuChem / GHRH literature |
| Somatotropic-axis research | GH pulsatility with long-acting GHRH | GHRH-analogue literature |
Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):
| Reported direction / finding | Context | Reference |
|---|---|---|
| Sustained GH/IGF-1 elevation over several days | healthy-volunteer study | Teichman SL et al., 2006 |
| DAC albumin binding extends half-life to ~6–8 days | pharmacokinetic studies | GHRH-analogue literature |
For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.
Dosing & Reconstitution Reference
Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.
| Parameter | Reference value |
|---|---|
| Research dose range (literature) | ≈ 1–2 mg per injection (DAC form), every 5–8 days, in study protocols |
| Reconstitution solvent | Bacteriostatic water (0.9% benzyl alcohol) |
| Storage (lyophilized) | −20°C, protected from light |
| Storage (reconstituted) | 2–8°C, up to ~2–4 weeks |
| Do not use | If the solution is cloudy or contains particulates |
Safety Profile
Published research observations, provided for reference only. This material is not for human or veterinary use.
| Category | Published observations |
|---|---|
| Local tolerability | Mild injection-site reactions |
| Hormonal | No significant prolactin or cortisol elevation (GHRH mechanism) |
| Immunogenicity | Low to moderate (DAC conjugate) |
| Status | For research use only; not for human or veterinary application |
Physicochemical Properties
| Property | Value |
|---|---|
| Physical state | White to off-white lyophilized powder |
| Solubility (water) | Soluble |
| logP | ≈ −2.0 (hydrophilic) |
| pH (reconstituted) | 5.0–7.0 |
| Stability (lyophilized) | ≥ 24 months at −20°C |
Synthesis & Manufacturing
CJC-1295 is built by Fmoc solid-phase synthesis of the modified GHRH(1–29) sequence; the DAC form then has a maleimidopropionyl-linker group conjugated to a lysine side chain, which is what lets it bind albumin in vivo.
| Step | Detail |
|---|---|
| Strategy | Fmoc solid-phase peptide synthesis |
| Resin | Rink amide / Wang resin |
| Core modifications | D-Ala², Gln⁸, Ala¹⁵, Leu²⁷ substitutions |
| DAC conjugation | Maleimide-linker group on a Lys side chain (DAC form) |
| Cleavage | TFA / TIPS / H₂O with scavengers |
| Purification | Preparative RP-HPLC (C18, TFA/ACN gradient) |
- Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
- Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
- Critical quality attributes: correct molecular weight and low deletion-peptide content. The DAC and no-DAC forms are distinguished by mass; confirm the modification.
Analytical Methods
| Method | Parameter | Typical result |
|---|---|---|
| RP-HPLC (C18, UV 214 nm) | Purity | ≥ 98% |
| HPLC retention | C18, reversed-phase TFA/ACN gradient | Single main peak |
| ESI-MS (positive mode) | Identity / mass | differs between the DAC and no-DAC forms |
| MALDI-TOF | Mass confirmation | differs between the DAC and no-DAC forms |
| Amino-acid analysis | Composition | Consistent with the stated sequence |
| LC-MS (extracted ion) | Deletion-peptide impurities | Within specification |
| Karl Fischer | Water content | < 6% |
| LAL assay | Endotoxin | Within specification |
| Ion chromatography | Residual TFA | < 500 ppm |
Representative RP-HPLC purity method:
- Column: C18, 5 µm, 250 × 4.6 mm
- Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
- Gradient: reversed-phase TFA/ACN gradient · Flow rate: 1.0 mL/min · Detection: UV 214 nm
- Confirmatory LC-MS: ESI positive mode (differs between the DAC and no-DAC forms). The DAC and no-DAC forms are distinguished by mass; confirm the modification.
Stability Data
Representative stability behaviour under common storage, handling and formulation conditions.
| Condition | Duration | Result |
|---|---|---|
| Lyophilized, −20°C, dark | ≥ 24 months | No significant degradation (purity > 97%) |
| Lyophilized, 2–8°C, dark | ≥ 12 months | Minimal degradation (purity > 95%) |
| Lyophilized, 25°C (accelerated) | 3 months | < 5% degradation |
| Reconstituted, 2–8°C, dark | 7–14 days | Minor degradation |
| Reconstituted, 25°C | 24–48 h | Use promptly |
| Light exposure (ICH Q1B) | 1.2 M lux·h | Generally light-stable |
| Freeze–thaw (−20°C ⇄ 25°C) | 3 cycles | Acceptable — aliquot to avoid repeats |
- Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
- Minimise freeze-thaw cycles; aliquot material used across many sessions.
- Key factor: The DAC and no-DAC forms are distinguished by mass; confirm the modification.
Selected References
- Teichman SL, et al. Prolonged stimulation of GH and IGF-1 secretion by a long-acting GHRH analogue (CJC-1295) in healthy adults. Journal of Clinical Endocrinology & Metabolism, 2006.
- GHRH-analogue and DAC albumin-binding technology literature.
Quality & Supply
- HPLC ≥ 98% purity with a Certificate of Analysis per batch
- Identity confirmed by LC-MS; DAC and no-DAC forms available
- Research samples through to bulk, with worldwide delivery
- Custom quantities and packaging on request
Need CJC-1295 — sample or bulk?
HPLC-verified, COA per batch. Tell us the quantity you need.
